Gene · 54915
Papers3,036
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,036
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| METTL3-mediated m6A modification stabilizes COL1A1 mRNA to promote extracellular matrix accumulation in keloids. | Exp Cell Res | 2026 | 42409157 | PubTator, text mining | PubMed |
| The role of RNA modifications in cancer translational control. | RNA Biol | 2026 | 42343618 | PubTator, text mining | PubMed |
| METTL3/YTHDF1-Driven SURF6 Promotes Prostate Cancer Stemness via CDK4. | J Cell Mol Med | 2026 | 42337991 | PubTator, text mining | PubMed |
| Ultrasound-programmable tumor extracellular vesicles delivery system for dual immune-epigenetic therapy against colorectal cancer metastasis. | J Control Release | 2026 | 42309466 | PubTator, text mining | PubMed |
| Expression of YTHDF1 and YTHDF2 in lung squamous cell carcinoma and their correlation with PD-L1. | J Thorac Dis | 2026 | 42306733 | PubTator, text mining | PubMed |
| YTHDF1 enhances ACSL3 translation in an m6A-dependent manner to regulate lipid metabolism and colorectal cancer progression. | Transl Cancer Res | 2026 | 42305514 | PubTator, text mining | PubMed |
| Alcohol-Induced Metabolic Stress Sensed by m6A-Modified ChREBP Drives Immune Evasion in Esophageal Carcinogenesis. | Cancer Res | 2026 | 42214005 | PubTator, text mining | PubMed |
| Analysis of RUVBL2 expression in malignant melanoma and its correlation with prognosis and immune infiltration. | Ital J Dermatol Venerol | 2026 | 42189027 | PubTator, text mining | PubMed |
| m1A Epitranscriptomic Control of NUPR1 by YTHDF1 Exacerbates Metabolic Dysregulation in Nonalcoholic Fatty Liver Disease. | J Clin Transl Hepatol | 2026 | 42181846 | PubTator, text mining | PubMed |
| m6A modification-mediated lncRNA UNC5B-AS1 enhances HCC progression through miR-760/IL6 axis. | Sci Rep | 2026 | 42178363 | PubTator, text mining | PubMed |
| The role of RNA modifications in the pathological mechanisms and therapeutic targeting of multiple myeloma. | Mol Cell Probes | 2026 | 42177998 | PubTator, text mining | PubMed |
| m6A-mediated CABLES1 translation potentiates tumor radioresistance via facilitating nonhomologous end-joining repair. | Cell Death Differ | 2026 | 42103895 | PubTator, text mining | PubMed |
| m6A Methyltransferase METTL3 Regulates Inflammatory and Immune Microenvironments in Renal Cell Carcinoma via Modulation of the PI3K/AKT Pathway. | Int J Genomics | 2026 | 42064710 | PubTator, text mining | PubMed |
| METTL5 reprograms glycolytic metabolism and promotes non-small cell lung cancer progression by modifying PGAM1. | Oncol Lett | 2026 | 42057886 | PubTator, text mining | PubMed |
| YTHDF1/SLC39A4 signaling axis promotes gastric cancer cell proliferation by suppressing cuproptosis ex vivo and in vitro. | Cancer Gene Ther | 2026 | 42056258 | PubTator, text mining | PubMed |
| RNA‑binding proteins as epithelial transcriptome orchestrators in gastric cancer: Immune‑metabolic crosstalk and therapeutic vulnerability (Review). | Int J Mol Med | 2026 | 41992985 | PubTator, text mining | PubMed |
| mRNA m6A modifications and the RNA-binding protein YTHDF1 affect translational control in both normal and pathological learning. | Proc Natl Acad Sci U S A | 2026 | 41973927 | PubTator, text mining | PubMed |
| Targeting m6A Reader YTHDF1 Enhances Antitumor Immunity and Potentiates Anti-PD-L1 Efficacy in Intrahepatic Cholangiocarcinoma. | Adv Sci (Weinh) | 2026 | 41969240 | PubTator, text mining | PubMed |
| Regulation of SLC7A11 by METTL3 induces cisplatin resistance in esophageal cancer. | Int J Biol Macromol | 2026 | 41967541 | PubTator, text mining | PubMed |
| Poxvirus infection triggers remodeling of host m⁶A epitranscriptome and benefits from the m⁶A regulatory responses. | Virol J | 2026 | 41965674 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54915/papers?page=2